New approaches in the diagnosis and treatment of multiple myeloma (review)
https://doi.org/10.58708/2074-2088.2024-2(32)-23-28
Abstract
Multiple myeloma is a malignant neoplasm caused by the uncontrolled proliferation of tumor plasma cells. With the introduction of new drugs and treatments in the last decade, the response rate and overall survival rate of MM patients have increased. However, MM remains an incurable disease with relapses or refractoriness to treatment. Therefore, the search for prognostic factors is a constant topic of study in many researches. Due to the application of modern technologies in diagnostics, it has become possible to identify a group of patients at high risk at an early stage. This allows the development of new treatment strategies. This review presents new achievements in the diagnosis and treatment of MM.
About the Authors
Zh. M. Kozich
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
V. N. Martinkov
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
N. N. Klimkovich
Институт повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»
Belarus
Belarus
T. V. Rudenkova
Институт повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»
Belarus
Belarus
S. A. Kostyuk
Институт повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»
Belarus
Belarus
N. V. Serdyukova
ГУ «Минский НПЦ хирургии, трансплантологии и гематологии»
Belarus
Belarus
References
1. Palumbo, A. Multiple myeloma / A. Palumbo, K.N. Anderson // Engl J Med. – 2011. – Т. 1046. – P. 10.
2. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells / E. Pérez-Persona [et al.] // Blood, The Journal of the American Society of Hematology. – 2007. – Т. 110. – №. 7. – P. 2586-2592.
3. Durie, B.G.M. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival / B.G.M. Durie, S.E. Salmon // Cancer. – 1975. – Т. 36. – №. 3. – P. 842-854.
4. International staging system for multiple myeloma / P.R. Greipp [et al.] // Journal of clinical oncology. – 2005. – Т. 23. – №. 15. – P. 3412-3420.
5. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma / S.V. Rajkumar [et al.] // The lancet oncology. – 2014. – Т. 15. – №. 12. – P. e538-e548.
6. Rajkumar, S.V. Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management / S.V. Rajkumar // American journal of hematology. – 2016. – Т. 91. – №. 7. – P. 719-734.
7. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation / A.C. Rawstron [et al.] // Blood, The Journal of the American Society of Hematology. – 2002. – Т. 100. – №. 9. – P. 3095-3100.
8. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology / E. Cannizzo [et al.] //Cytometry Part B: Clinical Cytometry. – 2010. – Т. 78, №4. – P. 231-238.
9. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders / A.C. Rawstron [et al.] // Haematologica. – 2008. – Т. 93, №3. – P. 431-438.
10. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma / N. Puig [et al.] // Cancers. – 2021. – Т. 13, №19. – P. 4924.
11. VS38c and CD38-multiepitope antibodies provide highly comparable minimal residual disease data in patients with multiple myeloma / A. Broijl [et al.] // American Journal of Clinical Pathology. – 2022. – Т. 157, №4. – P. 494-497.
12. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab / K.T. Soh [et al.] //Cytometry Part B: Clinical Cytometry. – 2021. – Т. 100, №4. – P. 497-508.
13. Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network / D.H. Bruinink [et al.] // Haematologica. – 2021. – Т. 106, №5. – P. 1496.
14. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma / J. Flores‐Montero [et al.] // Cytometry Part B: Clinical Cytometry. – 2016. – Т. 90, №1. – P. 61-72.
15. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience / H. Avet-Loiseau [et al.] // Journal of clinical oncology. – 2013. – Т. 31, №22. – P. 2806.
16. Hanamura, I. Multiple myeloma with highrisk cytogenetics and its treatment approach / I. Hanamura // International Journal of Hematology. – 2022. – Т. 115, №6. – P. 762-777.
17. A. Dhabe, Role of Conventional Cytogenetics and FISH in the Laboratory Work Up of Plasma Cell Dyscrasias / A. Dhabe, S. Das, M. Parihar // Indian Journal of Medical and Paediatric Oncology. – 2023.
18. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma / S. Kumar [et al.] // The lancet oncology. – 2016. – Т. 17, №8. – P. e328-e346.
19. Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges / G. Riva [et al.] //Cancers. – 2021. – Т. 13, №18. – P. 4582.
20. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma / J. Flores‐Montero [et al.] // Cytometry Part B: Clinical Cytometry. – 2016. – Т. 90, №1. – P. 61-72.
21. Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice /A. Gozzetti [et al.] //Journal of Personalized Medicine. – 2020. – Т. 10, №3. – P. 120.
22. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation / B. Paiva [et al.] // Blood. – 2008. – Vol. 112(10). – P. 4017-4023. https://doi.org/10.1182/blood-2008-05-159624.
23. Reuter, J.A. High-throughput sequencing technologies / J.A. Reuter, D.V. Spacek, M.P. Snyder // Molecular cell. – 2015. – Т. 58, №4. – P. 586-597. doi: 10.1016/j.molcel.2015.05.004
24. NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial / J.M. Rosa-Rosa [et al.] // Cancers. – 2022. – Т. 14, №20. – P. 5169. doi: 10.3390/cancers14205169
25. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma / J. Xu [et al.] // Proceedings of the National Academy of Sciences. – 2019. – Т. 116, №19. – P. 9543-9551. doi: 10.1073/pnas.1819745116.
26. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/ refractory multiple myeloma / D. Wang [et al.] // Blood, The Journal of the American Society of Hematology. – 2021. – Т. 137, №21. – P. 2890-2901. doi: 10.1182/blood.2020008936
Review
For citations:
Kozich Zh.M., Martinkov V.N., Klimkovich N.N., Rudenkova T.V., Kostyuk S.A., Serdyukova N.V. New approaches in the diagnosis and treatment of multiple myeloma (review). Medical and Biological Problems of Life Activity. 2024;(2):23-28. (In Russ.) https://doi.org/10.58708/2074-2088.2024-2(32)-23-28
Views: 65
Email this article 